Biotech_Leaders_horizontal_white

Main agenda

Capital markets, investment, partnerships, deal making & more

BOOK TICKETS

 

Day 1 – Wednesday 3rd May

09:00 LSX Welcome Address

Adam Griffiths, Senior Conference Director, Biotech Lead, LSX


09:05 Assessing Biotech Investment Trends in 2023 & Beyond

  • State of biopharma sector today – top line, bottom line, financial markets
  • Contemporary deal flow vs. historical norms
  • Impact of rally / downturn at time of presentation - how will other variables follow - IPO, private rounds
  • Boomerang to early-stage deals versus later stage deals
  • Inflation Reduction Act – impact on the sector, how companies are responding

Cody Powers, Principal - Portfolio & Pipeline, ZS Associates

Cody Powers, Principal - Portfolio & Pipeline, ZS Associates


09:30 Panel: Building Global Biotech Leader of Tomorrow – Shaping the Next Phase of Europe’s Booming Biotech Ecosystem

A tectonic shift in the biotech financing environment in recent years reached an all-time high of $104.7 billion, as biotech IPOs reached record levels in 2021 – 143 offerings totalling $19.3 billion. Fast forward through 2022, listings have dried up, valuations have dropped, and companies are faced with more difficult access to both private and public capital leaving some companies facing existential challenges. The unforeseeable geopolitical environment along with the post-pandemic landscape created difficult market conditions and new challenges, leaving the industry faced with more uncertainty in the immediate future; the skills to navigate these unprecedented challenges will be essential for the biotech C-suite. Executives of Europe’s leading life biotech companies, investors, and key stakeholders discuss the next wave of new challenges facing biotech leaders in 2023 and beyond, evidence of Europe’s successes, and potential improvements of the industry to strategically build an ever-stronger globally competitive powerhouse.

  • What are the financing challenges 2023 and what can we learn from 2022 to be better prepared for uncertainty?
  • Reduced access to capital forced a barrage of restructurings and a potential increased desirability for acquisition. While an M&A rebound is expected, is that a reality?
  • Access to the US market and building a transatlantic footprint remains paramount but where has Europe excelled and demonstrated leadership?
  • How are fund changing their allocation of capital? Does the way that funds are structured create an intrinsic problem for the industry?

Moderator: Mark Dorff, Partner, Brown Rudnick
Monika Vnuk,
MD, Blackstone Life Sciences
Ryan Richardson,
Chief Strategy Officer, BioNTech
Nanna Lüneborg,
General Partner, Forbion
Andrew Levin,
Managing Partner, RA Capital Management

Mark Dorff, Partner, Brown RudnickMonika Vnuk, VP Worldwide Business Development, Pfizer 300xRyan Richardson, Chief Strategy Officer, BioNTechNanna Lüneborg, General Partner, ForbionAndrew Levin, Managing Partner, RA Capital Management


10:30 Morning Break


 

CAPITAL MARKETS & INVESTMENT


11:10 Panel: Leading the Way in Today’s Global Investment Landscape – New Innovations, Strategies and Future Outlook

It’s no secret that the funding environment took a major shock and reset in 2022. However, no matter what the current geopolitical climate or state of the capital markets, innovation continues at ever-increasing speed and this innovation needs funding. Investors continue to raise record breaking levels of capital from LPs through new and recharged funds, so will 2023 see an upturn? Unexpected events create unexpected challenges, and unexpected challenges breed new opportunities. Leading investors discuss the global investment landscape and shifts in public and private finance, as well as what they expect 2023 and onwards to hold.

  • Where are the safe havens, if any, during uncertain times?
  • Perspectives on the public markets and the trickle-down effect on private funding
  • Is the investment community now prioritising early-stage investments?
  • Is competition for deals higher than ever? What can biotech companies, whatever stage they are at, do to ensure they are most attractive for investment?

Stephen Squinto, CIO, JP Morgan Life Sciences Private Capital
Stephanie Sirota, Partner & CBO, RTW Investments
Hakan Goker, MD, M Ventures
Graziano Seghezzi, Managing Partner, Sofinnova
John Cassidy, Investment Director Life Sciences & HealthTech, Softbank Vision Fund

Stephen Squinto, Chief Investment Officer, JP Morgan Life Sciences Private CapitalStephanie Sirota, Partner and CBO, RTW InvestmentsHakan Goker, Managing Director, M VenturesGraziano Seghezzi, Managing Partner, SofinnovaJohn Cassidy, Investment Director Life Sciences & HealthTech, Softbank Vision Fund


12:00 Panel: Investing in the New Landscape – Future Directions in Neurodegenerative Disease

Recognition that aging populations will give rise to new healthcare needs, and heightened awareness of mental health issue, is bringing renewed focus to neurological health. Dementia is the most common degenerative neurological condition in the United States, with most cases coming from Alzheimer’s disease. In 2021, 653 clinical development programs for medicines to treat neurological diseases, 43% of which are for neurodegenerative medicines. An expert panel discusses the investment needed to overcome these obstacles and explore the future of NDD research financing and commercialisation.

  • Current neurodegenerative drug development bottlenecks and progressing beyond them
  • Exploring transformative new platforms on the horizon for Alzheimer’s, ALS, Parkinson’s, Huntington’s and more
  • How to effectively incorporate novel research into drug development approach to maximize success commercially and in the clinic
  • How new mechanisms and modalities have opened doors for early-stage investment
  • Public market reception for neuro focused companies and the effect on M&A
David Reynolds, CEO, LoQus23
Jenny Barnett, CEO, Monument Therapeutics
Laurence Barker, Partner Dementia Discovery Fund, SV Health Investors

David Reynolds, CEO, LoQus 23Jenny Barnett, CEO, Monument TxLaurence Barker, CCBO, DDF, SV Health Investors 300x

PARTNERSHIPS & DEAL MAKING


11:10 Panel: The Next Era of Vaccinology: How Partnerships are Shaping the Future of Infectious Diseases

It has been a landmark year for vaccines with continued development of next-generation platforms and vaccines for unmet. needs. What comes next? Opportunities to develop global partnerships and collaboration is clearer than ever. A panel of trail-blazing experts share experience and insights and on the future of this technology and wider therapeutic area of infectious diseases.

  • How can new partnerships be leveraged to boost success?
  • How do we sustain R&D innovation?
  • The need for new human trial regulations to test vaccine efficacy – alternative routes to licensure?
  • What are the next most exciting opportunities in infectious diseases?

Holger Kissel, VP Business Alliances, BioNTech
Stig Tollefsen, Technology Office Lead, CEPI
Chris Cardon, CEO, Ziphius Vaccines
Ike James, Head of Technology Transfer, Medicines Patent Pool

Holger Kissel, Vice President, Business Alliances, BioNTechStig Tollefsen, Technology Office Lead, Coalition for Epidemic Preparedness Innovations (CEPI)Chris Cardon, CEO, Ziphius VaccinesIlk James, Head of Technology Transfer, Medicines Patent Pool


12:00 Panel: Future Horizons in Oncology Therapeutics and Global Deal-Making

Approved cell therapies have generated more than $2 billion in sales, and with novel oncology drugs being launched ta an increasing rate there is more opportunity today for oncology partnering than ever before.. New technologies and techniques offer the potential to address diseases with significant unmet needs (such as solid tumors, which represent more than 90 percent of adult cancers) and non-oncological conditions., however significant challenges remain which hinder a broader use.
  • Assessing the growing market for oncology drugs
  • The types of products are oncology drug marketers are looking for and typical deal terms
  • Current roadblocks, activities, and opportunities in oncology partnering in 2023
  • Significant trends in oncology deal-making and identifying remaining areas of unmet medical need
Jie D’Elia, SVP BD,Oncology & Haematology, Bristol Myers Squibb
Chris Brown,
Senior Director Oncology Worldwide BD, GSK
Faical Miyara,
Global Head Oncology Partnering, Ipsen
Sonal Patel,
VP Scientific Innovation Oncology, Johnson & Johnson Innovation

Jie D’Elia, SVP Business Development, Oncology & Haematology, Bristol Myers SquibbChris Brown, Senior Director, Oncology Worldwide Business Development, GSK Faical Miyara, Global Head Oncology Partnering, IpsenSonal Patel, Vice President, Scientific Innovation, Oncology, Johnson & Johnson

CAPITAL DEPLOYMENT & COMMERCIALISATION STRATEGY


11:10 Go-It-Alone or Partner? A Review of First Launch and Partnering Trends

  • A look at more than a decade of data for the US and EU markets (solo first launch, co-promote, out-license and key benchmarks)
  • A spotlight on lean commercialization models and launches <$500M in peak sales
  • Expert panel discussion and Q&A

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates


11:30 Panel: First Launch and Partnering Trends

Moderator: Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates

Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates


12:00 Panel: Biotech Valuation Tips, Tricks & Best Practices – Increasing the Value of your Company

Biotech companies with little to no revenue can still be worth billions. Despite facing some stiff headwinds, the biotech sector remains a strong engine for innovation, and small and emerging companies account for more than 50% of the current research and development pipeline. In uncertain times, with a market downturn and difficult geopolitical situations, how can a biotech company look to increase its value?

  • Why we need to understand biotech valuation, and why biotech pipeline valuation is different
  • Drug roulette? Switching business models to circumvent difficulties
  • Alternative strategies to increase value of the company
Moderator: Matthew Cardinal, VP, Strategy & Program Leadership, Halloran Consulting
Sven Kili, CEO, Antion Biosciences
Duncan Young, Head of Business Devleopment, Redx Pharma
Theo Harold, CEO, Crescendo Biologics
Bev Carr, CBO, Amphista Therapeutics
Giulia Vestri, Head of Business Development, Azafaros

Matthew Cardinal, VP Strategy & Program Leadership, Halloran Consulting GroupSven Kili, CEO, AntionDuncan Young, Sr. Director Business Development & Licencing, AstraZenecaTheodora Harold, CEO, Crescendo BiologicsBev Carr, CBO, Amphista TherapeuticsGiulia Vestri, Head of Business Development, Azafaros

12.50 Lunch Break


14:00 Panel: Early-stage Investment: What’s the New Normal for Biotech Funding?

Venture-capital funding and valuations for biotechnology start-ups remain high despite economic turmoil. For emerging biotech start-up companies, funding is one of the first challenges they will face and can influence the long-term success of a company. Spurred by the Covid-19 pandemic, new approaches to treating cancer, inflammatory diseases and other conditions have arrived, but how are they being sourced and funded?
A panel of expert early-stage investors with a keen eye for innovation discuss the latest innovations that excite them, their advice for biotech execs, and best practice in raising funds and positioning yourself as a leading, young company.

  • What are the top priority areas for investment and how are the latest discoveries and technological advances being sourced?
  • What are some of the factors which a company should possess to indicate they can be an attractive investment?
  • How will biotech early-stage funding change in the coming year?
  • How can founders and biotech execs prepare for the future?

Moderator: Samana Brannigan, Head of Health Technologies, UKRI
Alex Hamilton,
Partner, Syncona
Mary Canning,
Principal, Epidarex Capital
Søren Møller,
Managing Partner, Novo Seeds
Martin Pfister,
Principal, High-Tech Gründerfonds

Samana Brannigan, Innovation Lead and Investor Relations, Innovate UK 300xAlex Hamilton, Partner, SynconaMary Canning, Principal, Epidarex CapitalSoren MollerMartin Pfister, Investment Manager, High-Tech Gründerfonds


14:50 Panel: What I Wish I Had Known When Taking Assets to the US Market

Entering new markets comes with many challenges; intellectual property (IP) licensing, transactions, agreements – the list goes on. Entering the US market is becoming a strategic consideration ever-earlier in the growth process for many biotech companies, and experience, knowledge, and effective due diligence in navigating the whole process can save time, money, and headaches down the line. A multi-stakeholder panel will discuss how companies and their investors can optimize their IP portfolios for entry to the US, ensure long-term success in securing capital from investors, prepare for licensing and transactions, and minimize litigation risk.

  • How to put yourself in the best possible position for investment and deals
  • What assets investors and partners will want to see in your IP portfolio
  • How to protect privileged and confidential information during the due diligence process
  • Experience and lessons learned about ‘what I wish I had known’ and ‘what I think I could have done better’

Moderator: Gwilym Attwell, Patent Attorney, Fish & Richardson
Kieran Rooney, SVP, Head of BD, Amryt Pharma
Damien O’Farrell, Assistant General Counsel (Patents), GSK
Eliot Forster, CEO, F-star Therapeutics

Gwilym Attwell, Principal, Fish & RichardsonKieran Rooney, VP, Strategic Alliances and Licensing, Amryt PharmaDamien O’Farrell, Assistant General Counsel (Patents), GSKEliot_Forster

 


14:00 Panel: Accelerating Gene Therapies for Rare Disease Patients – Where Are the Bottlenecks & How Can We Overcome Them

New partnerships continue to emerge within the gene therapy field, but the past year has also flagged distinct development challenges that need to be overcome. Experts from pioneering companies and leading pharma the way to pinpoint these obstacles and explore how we can address them to bring gene therapies to patients more quickly, safely, and effectively:

  • Adapting to the novelty of gene therapies with respect to regulatory, pricing, market access, and patient needs
  • Accelerating gene therapy programs while maintaining safety and quality standards
  • How new partnerships are being leveraged to advance the field
  • Building out internal manufacturing capacity for commercial products
  • Exploring the concept of centres of excellence versus multi-centre gene therapy

Lori Badura, VP, Head of Global Neuroscience & Rare Disease Partnering, Ipsen
Jean-Philippe Combal,
CEO, Vivet Therapeutics
Martine Zimmerman,
SVP, Head of Regulatory & Quality Affairs, Alexion/AstraZeneca

Lori Badura, Global Head of Neurology and Immunology Business Development, Merck KGaAJean-Philippe Combal, CEO, Vivet TherapeuticsMartine Zimmerman, SVP, Head of Regulatory & Quality Affairs, AlexionAstraZeneca


14:50 Panel: Immuno-Inflammation: A Doorway to New Partners and Therapeutic Areas

Various dysfunctions in the immune system are the underlying cause for many health conditions, thus researching the mechanisms that drive these diseases can provide new insights across multiple therapeutic areas, ranging from neurodegenerative to cardiovascular diseases. Immuno-inflammation can also serve as a starting point leading to non-traditional partnerships between pharma, biotech, and research organisations. This panel gathers companies active in immunology & inflammation, discussing how they use this cross-indication response to identify R&D opportunities and inform their BD strategies.

  • How can we gain a better understanding of our patients’ journeys to achieve enhanced outcomes?
  • How can identifying new R&D opportunities inform BD strategies?
  • What partnerships can we form with patient groups, research institutions, public health authorities, and others in the industry across diseases?
  • What new innovations are coming down the pipeline, and how is the field as a whole developing? What are the future directions?

Andreas Sailer, Global Search & Evaluation Franchise Head, Immunology, Novartis
Rachel Strick, Head of Immunology BD & Acquisitions, AbbVie

Andreas Sailer, Global Search & Evaluation Franchise Head, Immunology, NovartisRachel Strick, Head of Immunology Business Development & Acquisitions, AbbVie


14:00 Panel: Starting With the End in Mind – Early Commercial Innovation & Planning

It may have previously been the norm to focus on clinical development and to leave commercial thinking to a bigger partner. However, as more and more companies choose to go it alone, or to do later stage deals, there is a need for asset owners to have a more granular understanding of their target market, the needs of their stakeholders, and the evidence required to ensure successful uptake and long-term differentiation

  • Forming your target product profiles and development strategy
  • Generating key data and information at every part of the development path
  • Having a commercial strategy to work towards and selling this to stakeholders, investors and
    partners


14:40 Fast-Tracking Drug Development Through Understanding Key Decision Factors When Outsourcing to CDMOs

CDMOs have operated on a business model which predominantly focused on serving as external service providers for manufacturing mature pharmaceuticals, however in recent years a dramatic shift in business models have occurred. CDMOs have increasingly become leaders of innovation and are covering more areas of the Drug Development pipeline from discovery and pre-clinical through the clinical phases to post commercialisation – but what does this mean for biotech and pharma?

  • Changing customer requirements leads to a change in business models
  • The role of CDMOs in the production of medicines today.
  • How these changes can be valuable to biotech and pharma

Jette Cowan, Head of Commercial – Pharmaceuticals, RSSL

Jette Cowan, Head Of Commercial – Pharmaceuticals, RSSL


15:00 Panel: Optimising the Value of your Asset For Entry Into the US and EU Market

Achieving a commercial transatlantic presence as a biotech requires gaining regulatory approval, and the development of a clear roadmap to overcome challenges in the development of assets. Increasing the value of assets as you and taking the right steps, can dramatically reduce the time taken to reach market approval.

  • How can we translate what we hear from regulatory bodies to inform our own internal decision-making?
  • Key milestones in asset development to provide you with clarity on both the potential and commerciality of programs.
  • Lessons learned and tangible takeaways anyone can apply to their programs, today.


15.40 Afternoon Break


16.20 Afternoon Keynote: Pharma’s New Era

The biopharma industry has weathered some storms in recent times, but the innovation, success stories and development of life saving treatments and cures continue to inspire. A ship is only as good as its captain and on rough seas and changing currents, strong leadership must endure.
  • Reimagining operating and business models
  • Patient-centricity to the core
  • The increasing role of digital
  • The biggest challenges ahead for the Pharma industry


16.50 Panel: Hold on to Your Hats And Dust Off Your Chequebooks: Pharma BD and M&A Outlook in 2023 and Beyond

In today’s business of drug development, lucrative deals and newly formed partnerships can be just as important as scientific breakthroughs. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. While recently we have seen a modest rebound after a slow start in 2022, whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Global leaders of pharma business development and M&A discuss the current climate, shifts in M&A strategies, the most exciting new areas of innovation, and their future outlook.

  • Through the last two years of the COVID-19 pandemic, a mainstay of the drug development community’s response has been collaboration, but will collaboration continue to be a critical paradigm for biopharmaceutical development?
  • Platform vs Product – Is there a preferred model when it comes to M&A?
    What are the factors which can reinforce any biotech’s chance for an acquisition whatever their focus?
  • What has got the world’s largest companies excited in 2023, and what new innovations has the M&A leaders excited?
  • M&A looking forward – what sort of deals will dominate pharma pipelines, and what will the current inaccessibility to capital mean for future valuations?

Moderator: Robbie McLaren, Vice Chair of the Global Life Sciences Practice, Latham & Watkins
Deborah Baron, SVP Worldwide Business Development, Pfizer
Matthias Müllenbeck, SVP Head Global BD & Alliance Management, Merck 
Nauman Shah, Global Head Janssen Business Development, Johnson & Johnson
Jane Buus Laursen, Corporate VP Business Development, Novo Nordisk
Elizabeth Mily, EVP Strategy & BD, Bristol Myers Squibb

Robbie McLaren, Partner, Latham & WatkinsDebbie Baron, SVP, Worldwide Business Development, PfizerMatthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaANauman Shah, Global Head, Janssen Business Development, Johnson & JohnsonJane Buus Laursen, Corporate Vice President Business Development, Novo NordiskElizabeth Mily, EVP Strategy & Business Development, Bristol Myers Squibb


17:40 Drinks Reception


18:30 Networking Party

 

 

Day 2 – Thursday 4th May

09:00 LSX Welcome Address

Adam Griffiths, Senior Conference Director, Biotech Lead, LSX


09:05 Keynote Fireside Chat: Pharma Spotlight

Getting ahead on disease and leading the way in modern drug development is one of the most inspiring challenges there is globally. Delivering ambition, strategy, and culture ensures a winning recipe for success.

  • New progress and company updates
  • Leading the way on the ESG agenda
  • Update on clinical pipeline and business development
  • 5-year outlook future priorities

Moderator: Clive Cookson, Science Editor, Financial Times
Joern-Peter Halle,
Chief Strategy Officer, Merck 

clivecooksonJoern-Peter Halle, Chief Strategy Officer, Merck KGaA-1


09:30 Panel: Biotech Leaders - Building a Galvanizing Culture & Successful Transatlantic Biotech

Growing a successful biotech into a lasting transatlantic business is no easy feat, and culture within an organisation can be its success or downfall. How do we build management teams and leadership structures to create an inspiring company culture, one that is felt throughout the business and lasts into the future? A multi-biotech panel discusses best practices, insights, and pro-tips into building an inspiring company with a growth mindset.

  • How does leadership shape company culture?
  • What do employees expect from their leadership in terms of culture in 2023 and how can we adapt?
  • How can company culture influence the hiring process?
  • How can a biotech begin to shape and mould its culture, into something new and established?
Jan van de Winkel, CEO, Genmab
Renee Aguiar-Lucander,
CEO, Calliditas
Alex Zhavoronkov,
CEO, Insilico Medicine
Florian Brand,
CEO, atai Life Sciences

Jan van de Winkel, CEO, GenmabRenee Aguiar-Lucander, CEO, Calliditas TherapeuticsAlex Zhavoronkov, CEO, Insilico Medicine (1)Florian Brand, CEO, ATAI Life Sciences


10:30 Morning Break


 

CAPITAL MARKETS & INVESTMENT


11:10 Panel: Mitigating Risks and Attracting Rewards – How To Capitalise and Spot Innovation

The past three years saw venture capitalists invest $52 billion into therapeutic-based biotech companies globally, with $35 billion of this going into startups with transformative platform technologies. This session explores how investors evaluate “the next big thing” and what biotech founders with novel or innovative technologies can do to put their best feet forwards.

  •  How investors evaluate risk, particularly when looking at new fields or technologies
  • Appetite for investing in novel biotechnologies vs platforms
  • How investors keep on top of new ideas and what grabs their interest (and what turns them off)
  • How to identify “must have” science early on
  • Building an effective founding team including crucial roles and qualities
  • Where to deploy capital at the outset and why

Simone Botti, Partner, INKEF Capital
Marianne Mertens,
Partner, Apollo Health Ventures
Sascha Berger,
General Partner, TVM Capital

Simone Botti, Partner, INKEF CapitalMarianne Mertens, Partner, Apollo Health VenturesSascha Berger


12:00 Panel: Navigating the Public Markets – Adapting to Shift in Dynamics

US biotech stock prices declined toward the end of 2021, following a bull run that started in 2020. Investors who had recently rejoiced in positive clinical news from public companies now fled from risk. Small-cap exchange-traded funds (ETFs) struggled against ETFs skewed toward mid- to large-cap biotechs. Although the recent downturn has been less severe for businesses with commercial-stage assets, most have been negatively affected.

  • Perspectives on the public markets and impacts its having on private funding
  • What are later-stage investors advising their portfolio and growing later stage biotechs
  • Strategies to navigate the current volatile market
  • How to develop a long-term value mindset

Victoria Darbyshire, Equity Analyst, J.P. Morgan
Tom Burt,
Partner, Sofinnova
Cathal Friel,
MD, Raglan Capital

Victoria Darbyshire, Equity Analyst, J.P. MorganTom Burt, Partner, SofinnovaCathal Friel, Managing Director, Raglan Capital

PARTNERSHIPS & DEAL MAKING


11:10 Panel: Emerging Pharma Deal-Making Take Centre stage – Shifts in Focus and New Opportunities

An increasing number of new and emerging deal makers at small pharma continue to make their mark, and with a shift towards commercialising products to serve orphan populations and specialist-treated conditions in recent years. While industry giants dominate the news, how are the Heads of BD and M&A at growing and emerging pharma viewing the landscape? A panel of top emerging pharma dealmakers discuss focus, strategy, and vision for becoming a lead player in the industry.

  • Product acquisition vs in-licensing – what factors affect the decision-making process?
  • How do emerging Pharma differentiate themselves and source aligned innovation
  • New focus areas for 2023
  • Are emerging pharma deal-making strategies evolving?

Sandra von Meier, Head BD & Licensing, Debiopharm International SA
Pavithra Sundaresan,
VP Head of External Innovation, Grünenthal
Jukka Muhonen,
VP Global BD & Alliances, Orion Pharma

Sandra von Meier, Head Business Development & Licensing, Debiopharm InternationalPavithra Sundaresan, Vice President, Head of External Innovation, Grünenthal Jukka Muhonen, Director of Global Business Development and Alliance Management, Orion Corporation


12:00 Panel : Early-Stage Pharma Partnering – Building a Strategy For Success

Partnerships with early-stage companies often spark some of the most innovative research and development collaborations in the healthcare industry. As breakthrough science continues to come from emerging biotech, the dynamics of innovation continue to evolve. The size, scale, expertise and connections of big pharma is still critical to the ecosystem, but are strategies changing? Pharma execs discuss how they are supporting innovation, sourcing and forming networks, and continuing to work to form win-win deals to partner with next wave biotechs.

  • How are the industry biggest players looking to source innovation sooner and support the youngest startups?
  • With a relative scarcity of capital are pharma seeing an increase in approaches for partnering?
  • What are the key considerations for companies in their partnering strategy approaching pharma? What is most commonly overlooked?
  • Which type of partnering at which stage?
Matthias Müllenbeck, SVP, Head Global Business Development & Alliance Management, Merck KGaA
Khatereh Ahmadi,
Head of Search & Evaluation European BD&L, MSD
Zaki Salanti, Head of S&E, Novo Nordisk

Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaAKhatereh Ahmadi, Head of Search and Evaluation Team, European BD&L Hub, MSDZaki Salanti, Head of S&E, Novo Nordisk

 

CAPITAL DEPLOYMENT & COMMERCIALISATION STRATEGY


11:10 Achieving buy-in & adoption from stakeholders for decentralized clinical trials

The COVID-19 pandemic has catalyzed the adoption of decentralized clinical trials while highlighting the critical benefits of virtual trials and improving the patient and physician experience. With benefits of DCTs progress now being realized, there is now more momentum than ever to perfect the processes and protocols to make DCTS more mainstream.

  • Discussing strategies to convey the value proposition and benefits of DCTs to stakeholders
  • Improving internal and external collaboration to maximize DCT success
  • Debating the potential methods to measure the success of DCTs


12:00 Panel: Attract, Retain, Develop – Building a Leading Executive Team & Board

Recruiting and attracting talent remains a key priority and increasing challenge as companies grow and the industry matures. Competition for roles with the right experience or training is higher than ever and with an increasing demand for hybrid or virtual workforce, how can biopharma organisations ensure the right people for their organisations. Executives discuss and tackle the biggest challenges in attracting, retaining talent and building out boards.

  • Small versus large company strategies and challenges
  • Should companies be building management teams and boards bigger and sooner as seen in the US??
  • How can companies work to maintain and retain top talent within their organization?

Keren Leshem, CEO, OCON Healthcare
Sarah Shackleton,
Chief Talent Officer, Oxford Science Enterprises
Edwin Moses,
former CEO Ablynx; Chairman, European biotechs
Stefano Portolano,
CEO, Azafaros
Anatole Klepatsky,
COO, Orion Biotechnology

Keren LeshemSarah Shackleton, Partner, Marketing & Talent, Abingworth 300xEdwinMosesStefano Portolano, CEO, AzafarosAnatole Klepatsky, COO, Orion Biotechnology 1

 


12:50  Lunch Break


14:00 Panel: Diversity & Inclusion in Biotech and Pharma – Optimising Internal DE&I Processes to Create an Inspiring & Inclusive Workplace Environment

Diversity and inclusion within biotech and pharma, remain behind most other industries for DEI initiatives. With a hunger for companies to create new initiatives which can bring them closer to a more diverse and all-encompassing organisation, this panel will take a deep and candid dive into strategies and best practices for pharma and biotech companies looking to improve their diversity efforts across all areas of their businesses.

  • How can we create an environment of inclusive leadership to build principles from the top down?
  • Recruiting and retaining diverse talent
  • Development of employee workgroups to better understand the employee experience
  • Strategies and metrics to build and track internal initiatives
Azurii Collier, Director, Enterprise Innovation, AbbVie; President-Elect, Women in Bio
Gerald Lee, Global Inclusion & Diversity Implementation Lead, GSK
Beatriz Rodriguez, SVP Talent, Inclusion & Diversity, Bayer
Roel Bulthuis, Managing Director, INKEF Capital
Quin Wills, CSO & Co-founder, Ochre Bio and Director, OUTbio

Azurii Collier, Director, Enterprise Innovation, AbbVie and President-Elect, Women in Bio (WIB)Gerald Lee, Global Inclusion & Diversity Implementation Lead, GSKBeatriz Rodriguez, SVP Talent, Inclusion & Diversity, BayerRoel Bulthuis, Managing Director, INKEF CapitalQuin Wills, CSO & Co-founder, Ochre Bio and Director, OUTbio


15:10 Panel: Preparing for the Return of the Biotech IPO – 2023 and Beyond

Whether your planned listing date is six or 16 months away, communications play a critical role in a successful IPO — up to and beyond listing day — and need to be executed with precision. The financials are important, but any business is much more than a balance sheet. Investors care about the story behind the company, what’s driving success quarter over quarter and year over year, the priorities informing your business, the core values of your company, the quality metrics, and the leadership team powering the mission forward. For biotech and healthcare companies considering the public markets in 2023, the time to execute on IPO-readiness communications efforts is now. A major consideration for any company, executives who have taken their businesses public in the US discuss the decision and timing their listing, how they managed during in a period of huge disruption and travel restrictions and key success factors in taking European companies to Nasdaq.

  • Key considerations for companies looking to tap the US public markets
  • What skills and experience are necessary to bring on to your board and management team for life on US public markets?
  • How have biotechs who have successfully undergone an IPO during the downturn navigated the process?
  • The European discount – is the perception of European companies being undervalued (or US companies overvalued) a reality?
  • What does your communications planning need to include for IPO-readiness?

    Tim Haines,
    Managing Partner, Abingworth Life Sciences
    Linden Thomson,
    Lead Manager, Healthcare Franchise, AXA Investment Managers
    Lone Henriksen,
    CEO, CS Medica
    Houman Ashrafian,
    Managing Partner, SV Health Investors

Tim Haines, Managing Partner, Abingworth Life ScienceLinden Thomson, Lead Manager, AXA IM Framlington BioTech Fund, Head, Healthcare Franchise, Co-Head, Global Equity, AXA Investment ManagersLone Henriksen, CEO, CS Medica Houman Ashrafian, Managing Partner, SV Health Investors


16:00 Close of Congress


DOWNLOAD BROCHURE